Please login to the form below

Not currently logged in
Email:
Password:

CAR therapies

This page shows the latest CAR therapies news and features for those working in and with pharma, biotech and healthcare.

Industry frustrated by late warning on 'no deal' Brexit disruption

Industry frustrated by late warning on 'no deal' Brexit disruption

One reason stockpiling isn’t a complete solution is that many medicines – such as the new CAR-T therapies - have a very short shelf-life, and cannot simply be stored in

Latest news

More from news
Approximately 1 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    Most notably, fast patient access for CAR-T cell therapies, Gilead’s Yescarta and Novartis’ Kymriah, where England has been ahead of its European counterparts in making the drugs available. ... CAR-T therapies are cost-effective for these patients,

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    Diagnosis. As with many new rare disease therapies, one of the biggest challenges for Alnylam is to bring as many patients as possible to diagnosis and then treatment. ... therapies, such as CAR-Ts Kymriah and Yescarta.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... molecular defects that are driving its

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    Current projects include developing antibodies for use as cancer imaging agents, antibody drug conjugates, chimeric antigen receptor therapies (CAR-Ts) and nano-medicines.

  • The good, the bad and the ugly The good, the bad and the ugly

    The oncology market is certainly evolving. “Some of the most interesting play is in immuno-oncology, where combination therapies are increasingly being explored. ... It will also be interesting to see how gene therapies and cell-based therapies, like

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics